Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

NCT01484080 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: BIBF + Paclitaxel
DRUG: Paclitaxel

Sponsor

Centro Nacional de Investigaciones Oncologicas CARLOS III

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]